Category - Developments

Closely held Implandata Ophthalmic Products of Germany has received CE Mark for its EYEMATE system, making it available for commercial use within the EU. The EYEMATE system provides intraocular pressure (IOP) readings...

Quidel (NASDAQ:QDEL) has acquired the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for about $14-million. InflammaDry is the only point-of-care test that detects elevated levels of MMP-9, a key...

An article on the Alzaforum website highlights IntelGenx (OTCQX:IGXT; TSXV:IGX) and its montelukast oral film candidate for the treatment of brain degenerative diseases, such as early-stage dementia. Alzaforum is a news...

An article in the latest issue of the weekly peer-reviewed journal, The BMJ, about arthroscopic surgery for degenerative knee arthritis and meniscal tears appears to dovetail with an approach by Ortho Regenerative...

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine was featured in an article about new developments in managing opioid addiction that was published in the peer-reviewed journal, Drug, Design...

Norgine, a European specialist pharmaceutical company, has agreed to acquire Merus Labs International (NASDAQ:MSLI; TSX:MSL) for $1.65 a share in cash, including the assumption of debt obligations, for a total...

Profound Medical (TSXV:PRN; OTCQX:PRFMF) posted revenue for the first time in the first quarter this year and reported that its TACT clinical trial to support a marketing application to the FDA for its TULSA-PRO device...

Histogenics (NASDAQ:HSGX) has successfully completed all formal consultations with the Office of Cellular and Tissue-based Products of the Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the marketing...

Theratechnologies’ (TSX:TH) partner, TaiMed Biologics of Taiwan, completed the submission of a biologics license application (BLA) to the FDA for ibalizumab for the treatment of multidrug-resistant human...

Microbix Biosystems (TSX:MBX) has consulted with the FDA regarding the company’s plans to return its thrombolytic biologic drug, Kinlytic, to the U.S. market. Microbix believes the results of its consultation will...